Alto Neuroscience, Inc. (ANRO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...

LOS ANGELES, CA / ACCESSWIRE / December 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto ...

William Blair has recently reduced Applied Therapeutics Inc (APLT) stock to Mkt Perform rating, as announced on December 23, 2024, according to Finviz. Earlier, on December 2, 2024, UBS had reduced ...

JonesTrading analyst Justin Walsh initiated coverage with a Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report) today and set a price target of $18.00. The company’s shares closed ...

announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The ...

Vigil Neuroscience, Inc. has a 12-month low of $1.99 and a 12-month high of $6.06. The stock has a fifty day moving average of $3.24 and a 200-day moving average of $3.56.

SANTA CLARA, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Applied Materials, Inc. issued the following statement today regarding updated export regulations for semiconductor technology, announced by ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...